US Slaps 10% Tariff on Indian Imports — These 6 Companies Are Positioned to Win

US Slaps 10% Tariff on Indian Imports — These 6 Companies Are Positioned to Win

The US has imposed a 10% tariff on Indian imports under Section 301, sending jitters through export-heavy sectors. Textile stocks slumped, pharma names wobbled, and the financial press filled with doom. But buried in company filings is a more nuanced picture: several NSE-listed companies have quietly built structures — overseas plants, duty-free trade routes, and irreplaceable supply positions — that make them not just resilient to tariffs, but potential beneficiaries.

Here are six companies whose filings tell a different story from the headline panic.

Hindalco Industries: The Indian Company That Manufactures in America

Hindalco's wholly owned subsidiary Novelis is the world's largest flat-rolled aluminium producer and aluminium recycler. With $17.1 billion in revenue and $2.0 billion in adjusted EBITDA, Novelis operates 33 facilities globally — many of them on US soil.

The crown jewel is Novelis's $2.5 billion Bay Minette plant in Alabama, a 600-kiloton facility ramping up by FY26. Per Hindalco's earnings call, "approximately two-thirds of the production at this plant will be for the North America beverage packaging market where demand currently outpaces local supply." Management noted that North America is "the one market in the world that is undersupplied and is actually importing can body sheets into the U.S. coming from Asia, China."

The math works in Hindalco's favour: tariffs make imported aluminium more expensive, which strengthens the competitive position of Novelis's American-made product. This is an Indian-listed company that benefits when the US raises trade barriers.

Gokaldas Exports: The Kenya Detour Around US Tariffs

Gokaldas derives 72% of its consolidated revenue from the United States, making it appear deeply exposed. But management has built a structural hedge: manufacturing operations in Kenya, where 95% of output is exported to the US duty-free under AGOA — the African Growth and Opportunity Act.

Per Gokaldas's earnings transcript: "AGOA allows Kenya to export duty-free into United States... the underlying tariff ranges anywhere between 14% to 32%." While Indian garment exporters face the new 10% tariff on top of existing duties, Gokaldas's Kenya production enters the US at zero duty. The tariff actually widens Gokaldas's cost advantage over competitors who export directly from India.

PDS Limited: Turning Tariff Chaos into a Business Model

PDS Limited operates as a global sourcing platform with supply networks spanning Sri Lanka, Turkey, Egypt, Latin America, and India. When tariffs shift, PDS doesn't get disrupted — it gets busy.

Per their Q4 FY25 investor update, PDS highlighted the "ability to shift sourcing rapidly to regions with favorable trade terms" as a core strength, calling tariff disruption an "opportunity to attract global brands seeking tariff-optimized, compliant sourcing partners." The company recently acquired Knit Gallery to strengthen its India manufacturing presence and is positioning itself to capitalize on the UK-India FTA, building sourcing resilience across multiple trade corridors.

For PDS, every new tariff is a new reason for global brands to call.

The Pharma Trio: Dr. Reddy's, Cipla, and Sun Pharma

The proposed tariff on Indian generic drugs made dramatic headlines — "Trump's Tariffs Are Targeting Indian Drugmakers" — but the filings paint a picture of near-irreplaceability.

Dr. Reddy's reported that North America generics revenue crossed $1 billion for the second consecutive year, with overall EBITDA margins at 30% and return on capital employed at 35%. Revenue grew 20% in Q4 and 17% for the full fiscal year, per their quarterly results. With a net cash surplus of $614 million, the company has ample buffer to absorb cost pressures while retaining pricing power in a market where alternatives are scarce. Cipla delivered its highest-ever North America annual revenue at $934 million, driven by what management described as "differentiated products" — complex generics and specialty molecules that competitors cannot easily replicate. The company has reported 15 consecutive quarters of revenue growth in North America, per its investor presentations, suggesting structural demand rather than cyclical luck. Sun Pharma crossed a major milestone: its US Innovative Medicines business exceeded $1 billion in revenue, surpassing its generics operation in the US for the first time. The launch of Leqselvi for severe alopecia areata in the United States and 4 new generic product launches in Q1 alone demonstrate a portfolio that the US healthcare system cannot simply source elsewhere.

The reality is that India supplies roughly 40% of US generic drug volume. No tariff can conjure alternative manufacturing capacity overnight — meaning Indian pharma companies retain extraordinary pricing leverage. Any tariff cost is likely passed through to US buyers, not absorbed by Indian margins.

What Retail Investors Should Do

Tariff headlines create volatility, and volatility creates opportunity. Before panic-selling an exporter, check three things in their filings: What percentage of revenue comes from the US? Do they have manufacturing or sourcing in tariff-exempt countries? Is their product easily substitutable?

Companies with third-country production (Gokaldas's Kenya), US-based manufacturing (Hindalco's Novelis), or irreplaceable supply positions (Indian pharma) are structurally different from companies that simply ship goods from India to America. The tariff impact is real for the latter group — textile companies like Welspun Living have already flagged tariff rates as high as 25-50% as a risk in their filings — but the winners are hiding in the same news cycle.

As always, the smartest money reads the filings, not just the headlines.

Data sourced from company filings on NSE via Xaro.